Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
P/B ratio for Vir Biotechnology, Inc. (VIR)
P/B ratio as of 2023: 0.85
According to Vir Biotechnology, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.85. At the end of 2022 the company had a P/B ratio of 1.62.
P/B ratio history for Vir Biotechnology, Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.85 |
| 2022 | 1.62 |
| 2021 | 3.80 |
| 2020 | 4.45 |
| 2019 | 3.19 |
| 2018 | -7.58 |
| 2017 | -19.72 |